Obesity and colorectal cancer

Postgraduate Medical Journal

Volumn 89, Issue 1055, 2013, Pages 519-533

  Bardou, Marc ^a,b   Barkun, Alan N ^c,d   Martel, Myriam ^c  

^a HÔPITAL DU BOCAGE   (France)

^b Institut Médical de Génétique et d Immunologie   (France)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BEVACIZUMAB; BILE ACID; CETUXIMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MISMATCH REPAIR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RESISTIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D;

ABDOMINAL OBESITY; ARTICLE; BARIATRIC SURGERY; BODY MASS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DEATH; DISEASE ASSOCIATION; EXERCISE; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORTALITY; OBESITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 84882258267     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2013-304701rep     Document Type: Article

References (184)

1. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
2. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307:483-90.
3. Bogossian FE, Hepworth J, Leong GM, et al. A cross-sectional analysis of patterns of obesity in a cohort of working nurses and midwives in Australia, New Zealand, and the United Kingdom. Int J Nurs Stud 2012;49:727-38.
4. Charles MA, Eschwege E, Basdevant A. Monitoring the obesity epidemic in France: the Obepi surveys 1997-2006. Obesity (Silver Spring) 2008;16:2182-6.
5. Xi B, Liang Y, He T, et al. Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993-2009. Obes Rev 2012;13:287-96.
6. Abajo A, Bitarte N, Zarate R, et al. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol 2012;18:637-45.
7. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
8. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008;168:1617-24.
9. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:1609-16.
10. Golan R, Shelef I, Rudich A, et al. Abdominal superficial subcutaneous fat: a putative distinct protective fat subdepot in type 2 diabetes. Diabetes Care 2012;35:640-7.
11. Evans PD, McIntyre NJ, Fluck RJ, et al. Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3. PLoS One 2012;7:e34699.
12. Lovejoy JC,de la Bretonne JA, Klemperer M, et al. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 1996;45:1119-24.
13. Albu JB, Murphy L, Frager DHJ, et al. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes 1997;46:456-62.
14. Carroll JF, Fulda KG, Chiapa AL, et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity (Silver Spring) 2009;17:1420-7.
15. Andrieu N, Launoy G, Guillois R, et al. Familial relative risk of colorectal cancer: a population-based study. Eur J Cancer 2003;39:1904-11.
16. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
17. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
18. Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer 2010;126:692-702.
19. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002;66:987-992.
20. Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-30.
21. Harriss DJ, Atkinson G, George K, et al. Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. Colorectal Dis 2009;11:547-63.
22. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 2010;11:19-30.
23. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol 2007;13:4199-206.
24. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. Bmc Public Health 2009;9:88.
25. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007;86:556-65.
26. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007;16:2533-47.
27. Matsuo K, Mizoue T, Tanaka K, et al. Association between body mass index and the colorectal cancer risk in Japan: pooled analysis of population-based cohort studies in Japan. Ann Oncol 2012;23:479-90.
28. Bassett JK, Severi G, English DR, et al. Body size, weight change, and risk of colon cancer. Cancer Epidem Biomar 2010;19:2978-86.
29. Laake I, Thune I, Selmer R, et al. A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon. Cancer Epidemiol Biomarkers Prev 2010;19:1511-22.
30. Odegaard AO, Koh WP, Yu MC, et al. Body mass index and risk of colorectal cancer in Chinese Singaporeans: the Singapore Chinese Health Study. Cancer 2011;117:3841-9.
31. Burton A, Martin R, Galobardes B, et al. Young adulthood body mass index and risk of cancer in later adulthood: historical cohort study. Cancer Causes Control 2010;21:2069-77.
32. Chen J, Iverson D. Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer. Cancer Causes Control 2012;23:1767-73.
33. Ben Q, An W, Jiang Y, et al. Body mass index increases risk for colorectal adenomas based on meta-analysis. Gastroenterology 2012;142:762-72.
34. Hong S, Cai Q, Chen D, et al. Abdominal obesity and the risk of colorectal adenoma: a meta-analysis of observational studies. Eur J Cancer Prev 2012;21:523-31.
35. Myung SK, Lee YJ, Cho B, et al. Adiposity and the risk of colorectal adenomatous polyps: a meta-analysis. Cancer Cause Control 2011;22:1021-35.
36. Okabayashi K, Ashrafian H, Hasegawa H, et al. Body mass index category as a risk factor for colorectal adenomas: a systematic review and meta-analysis. Am J Gastrenterol 2012;107:1175-1185; quiz 86.
37. Kim BC, Shin A, Hong CW, et al. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control 2012;23:727-35.
38. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
39. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61.
40. Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009;17:796-802.
41. Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10:653-62.
42. Rapp K, Klenk J, Ulmer H, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol 2008;19:641-8.
43. Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 2011;60:1214-23.
44. Nugent C, Bai C, Elariny H, et al. Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg 2008;18:1278-86.
45. Garcia, de la Torre N, Rubio MA, Bordiu E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008;93:4276-4281.
46. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003;98:484-95.
47. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008;26:4109-15.
48. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:1647-54.
49. Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012;30:42-52.
50. Matthews CE, Sui X, LaMonte MJ, et al. Metabolic syndrome and risk of death from cancers of the digestive system. Metabolism 2010;59:1231-9.
51. Haydon AM, Macinnis RJ, English DR, et al. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62-7.
52. Wolin KY, Yan Y, Colditz GA, et al. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009;100:611-6.
53. Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a meta-analysis. Br J Cancer 2011;104:882-5.
54. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.
55. Guilera M, Connelly-Frost A, Keku TO, et al. Does physical activity modify the association between body mass index and colorectal adenomas? Nutr Cancer 2005;51:140-5.
56. Winzer BM, Whiteman DC, Reeves MM, et al. Physical activity and cancer prevention: a systematic review of clinical trials. Cancer Causes Control 2011;22:811-26.
57. Song BK, Cho KO, Jo Y, et al. Colon transit time according to physical activity level in adults. J Neurogastroenterol Motil 2012;18:64-9.
58. Robertson G, Meshkinpour H, Vandenberg K, et al. Effects of exercise on total and segmental colon transit. J Clin Gastroenterol 1993;16:300-3.
59. Neuhouser ML, Manson JE, Millen A, et al. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin d with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 2012;175:673-84.
60. Earthman CP, Beckman LM, Masodkar K, et al. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 2012;36:387-96.
61. Rosen AB, Schneider EC. Colorectal cancer screening disparities related to obesity and gender. J Gen Intern Med 2004;19:332-8.
62. Maruthur NM, Bolen S, Gudzune K, et al. Body mass index and colon cancer screening: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:737-46.
63. Messina CR, Lane DS, Anderson JC. Body mass index and screening for colorectal cancer: gender and attitudinal factors. Cancer Epidemiol 2012;36:400-8.
64. Zhou Y, Wu L, Li X, et al. Outcome of laparoscopic colorectal surgery in obese and nonobese patients: a meta-analysis. Surg Endosc 2012;26:783-9.
65. Makino T, Shukla PJ, Rubino F, et al. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection. Ann Surg 2012;255:228-36.
66. Akiyoshi T, Ueno M, Fukunaga Y, et al. Effect of body mass index on short-term outcomes of patients undergoing laparoscopic resection for colorectal cancer: a single institution experience in Japan. Surg Laparosc Endosc Percutan Tech 2011;21:409-14.
67. Ballian N, Yamane B, Leverson G, et al. Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma. Ann Surg Oncol 2010;17:1606-13.
68. Bege T, Lelong B, Francon D, et al. Impact of obesity on short-term results of laparoscopic rectal cancer resection. Surg Endosc 2009;23:1460-4.
69. Blee TH, Belzer GE, Lambert PJ. Obesity: is there an increase in perioperative complications in those undergoing elective colon and rectal resection for carcinoma? Am Surg 2002;68:163-6.
70. Blumberg D. Laparoscopic colectomy performed using a completely intracorporeal technique is associated with similar outcome in obese and thin patients. Surg Laparosc Endosc Percutan Tech 2009;19:57-61.
71. Chern H, Chou J, Donkor C, et al. Effects of obesity in rectal cancer surgery. JAm Coll Surg 2010;211:55-60.
72. Damadi AA, Julien L, Arrangoiz R, et al. Does obesity influence lymph node harvest among patients undergoing colectomy for colon cancer? Am Surg 2008;74:1073-7.
73. Healy LA, Ryan AM, Sutton E, et al. Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis 2010;25:1293-9.
74. Ishii Y, Hasegawa H, Nishibori H, et al. Impact of visceral obesity on surgical outcome after laparoscopic surgery for rectal cancer. Br J Surg 2005;92:1261-2.
75. Kang J, Baek SE, Kim T, et al. Impact of fat obesity on laparoscopic total mesorectal excision: more reliable indicator than body mass index. Int J Colorectal Dis 2012;27:497-505.
76. Karahasanoglu T, Hamzaoglu I, Baca B, et al. Impact of increased body mass index on laparoscopic surgery for rectal cancer. Eur Surg Res 2011;46:87-93.
77. Linebarger JH, Mathiason MA, Kallies KJ, et al. Does obesity impact lymph node retrieval in colon cancer surgery? Am J Surg 2010;200:478-82.
78. Merkow RP, Bilimoria KY, McCarter MD, et al. Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg 2009;208:53-61.
79. Nitori N, Hasegawa H, Ishii Y, et al. Impact of visceral obesity on short-term outcome after laparoscopic surgery for colorectal cancer: a single Japanese center study. Surg Laparosc Endosc Percutan Tech 2009;19:324-7.
80. Park JS, Choi GS, Jang YS, et al. Influence of obesity on the serum carcinoembryonic antigen value in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010;19:2461-8.
81. Poulsen M, Ovesen H. Is laparoscopic colorectal cancer surgery in obese patients associated with an increased risk? Short-term results from a single center study of 425 patients. J Gastrointest Surg 2012;16:1554-8.
82. Sakamoto K, Niwa S, Tanaka M, et al. Influence of obesity on the short-term outcome of laparoscopic colectomy for colorectal cancer. J Minim Access Surg 2007;3:98-103.
83. Singh A, Muthukumarasamy G, Pawa N, et al. Laparoscopic colorectal cancer surgery in obese patients. Colorectal Dis 2011;13:878-83.
84. Tsujinaka S, Konishi F, Kawamura YJ, et al. Visceral obesity predicts surgical outcomes after laparoscopic colectomy for sigmoid colon cancer. Dis Colon Rectum 2008;51:1757-1765; discussion 65-7.
85. Yamamoto N, Fujii S, Sato T, et al. Impact of body mass index and visceral adiposity on outcomes in colorectal cancer. Asia Pac J Clin Oncol 2012;8:337-45.
86. Park JW, Lim SW, Choi HS, et al. The impact of obesity on outcomes of laparoscopic surgery for colorectal cancer in Asians. Surg Endosc 2010;24:1679-85.
87. Sarkanen JR, Kaila V, Mannerstrom B, et al. Human adipose tissue extract induces angiogenesis and adipogenesis in vitro. Tissue Eng Part A 2012;18:17-25.
88. Chen J, Katsifis A, Hu C, et al., Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. Curr Drug Discov Technol 2011;8:119-125f.
89. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341-7.
90. Ghiringhelli F, Vincent J, Guiu B, et al. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs 2012;30:758-64.
91. Simkens LH, Koopman M, Mol L, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer 2011;47:2560-7.
92. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
93. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629-39.
94. Karelis AD. Metabolically healthy but obese individuals. Lancet 2008;372:1281-3.
95. Stocks T, Lukanova A, Bjorge T, et al. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2010. Published Online First: 17 December 2010.
96. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 2008;32:304-14.
97. Hu NC, Chen JD, Lin YM, et al. Stepwise relationship between components of metabolic syndrome and risk of colorectal adenoma in a Taiwanese population receiving screening colonoscopy. J Formos Med Assoc 2011;110:100-8.
98. Kim JH, Lim YJ, Kim YH, et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev 2007;16:1543-6.
99. Tsilidis KK, Brancati FL, Pollak M., et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2010;21:1-10.
100. Pelucchi C, Negri E, Talamini R, et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010;46:1866-72.
101. Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28-36.
102. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. Bmc Gastroenterol 2010;10:51.
103. Ashbeck EL, Jacobs ET, Martinez ME, et al. Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2009;18:1134-43.
104. Healy LA, Howard JM, Ryan AM, et al. Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients. Colorectal Dis 2012;14:157-65.
105. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007;86:s836-42.
106. Luo Z, Saha AK, Xiang X, et al. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
107. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-54.
108. Oh TH, Byeon JS, Myung SJ, et al. Visceral obesity as a risk factor for colorectal neoplasm. J Gastroenterol Hepatol 2008;23:411-17.
109. Yamaji T, Iwasaki M, Sasazuki S, et al. Visceral fat volume and the prevalence of colorectal adenoma. Am J Epidemiol 2009;170:1502-11.
110. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 2005;11:3642-6.
111. Yamamoto S, Nakagawa T, Matsushita Y, et al. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. Diabetes Care 2010;33:184-9.
112. Nam SY, Kim BC, Han KS, et al. Abdominal visceral adipose tissue predictsrisk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 2010;8:443-50.e1- 2.
113. Erarslan E, Turkay C, Koktener A, et al. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci 2009;54:862-8.
114. Barb D, Williams CJ, Neuwirth AK, et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86: s858-66.
115. Shehzad A, Iqbal W, Shehzad O, et al. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 2012;11:8-20.
116. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012;33:47-94.
117. Xu XT, Xu Q, Tong JL, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis 2011;12:234-44.
118. An W, Bai Y, Deng SX, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev 2012;21:126-33.
119. Gulcelik MA, Colakoglu K, Dincer H, et al. Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012;13:395-8.
120. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97:1688-94.
121. Lukanova A, Soderberg S, Kaaks R, et al. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006;15:401-2.
122. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010;101:1286-91.
123. Svobodova S, Topolcan O, Holubec L Jr, et al. Parameters of biological activity in colorectal cancer. Anticancer Res 2011;31:373-8.
124. Ferroni P, Palmirotta R, Spila A, et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res 2007;27:483-9.
125. Gialamas SP, Petridou ET, Tseleni-Balafouta S, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011;60:1530-8.
126. Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009;27:2751-7.
127. Landskroner-Eiger S, Qian B, Muise ES, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 2009;15:3265-76.
128. Man K, Ng KT, Xu A, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 2010;16:967-77.
129. Moon HS, Liu X, Nagel JM, et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut 2012 Published Online First: 26 June 2012.
130. Byeon JS, Jeong JY, Kim MJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 2010;127:2758-67.
131. Sun Y, Lodish HF. Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration. PLoS One 2010;5:e11987.
132. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008;57:1531-8.
133. Saxena A, Chumanevich A, Fletcher E, et al. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim Biophys Acta 2012;1822:527-36.
134. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
135. van Dielen FM, van't Veer C, Schols AM, et al. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001;25:1759-66.
136. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010;138:2029-43 e10.
137. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010;152:93-100.
138. Wallace AM, Sattar N, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res 1998;4:2977-9.
139. Arpaci F, Yilmaz MI, Ozet A, et al. Low serum leptin level in colon cancer patients without significant weight loss. Tumori 2002;88:147-9.
140. Stattin P, Palmqvist R, Soderberg S, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep 2003;10:2015-21.
141. Stattin P, Lukanova A, Biessy C, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004;109:149-52.
142. Tamakoshi K, Toyoshima H, Wakai K, et al. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 2005;68:454-61.
143. Ho GY, Wang T, Gunter MJ, et al. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012;72:3029-37.
144. Tutino V, Notarnicola M, Guerra V, et al. Increased soluble leptin receptor levels are associated with advanced tumor stage in colorectal cancer patients. Anticancer Res 2011;31:3381-3.
145. Wang D, Chen J, Chen H, et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J Biosci 2012;37:91-101.
146. Kumor A, Daniel P, Pietruczuk M, et al. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009;24:275-81.
147. Aloulou N, Bastuji-Garin S, Le Gouvello S, et al. Involvement of the leptin receptor in the immune response in intestinal cancer. Cancer Res 2008;68:9413-22.
148. Uddin S, Bavi PP, Hussain AR, et al. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009;30:1832-40.
149. Endo H, Hosono K, Uchiyama T, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011;60:1363-71.
150. Nakajima A, Endo H, Hosono K, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011;60:1363-71.
151. Aparicio T, Guilmeau S, Goiot H, et al. Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. Gastroenterology 2004;126:499-510.
152. Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut 2005;54:1136-45.
153. Drew JE. Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proc Nutr Soc 2011:1-6.
154. Chia VM, Newcomb PA, Lampe JW, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2007;16:2697-703.
155. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48.
156. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6.
157. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
158. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
159. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
160. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 2011;3:12.
161. Endo H, Hosono K, Fujisawa T, et al. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut 2009;58:1637-43.
162. Freier S, Weiss O, Eran M, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999;44: 704-8.
163. Yavari K, Taghikhani M, Maragheh M Ghannadi, et al. Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells. Int J Colorectal Dis 2010;25:9-16.
164. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010;126:1702-15.
165. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
166. Schoen RE, Weissfeld JL, Kuller LH, et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology 2005;129:464-75.
167. Soubry A, Il'yasova D, Sedjo R, et al. Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. Int J Cancer 2012;131:512-17.
168. Yamaji T, Iwasaki M, Sasazuki S, et al. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. Int J Obes (Lond) 2012;36:440-7.
169. Keku TO, Vidal A, Oliver S, et al. Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites. Cancer Causes Control 2012;23:1127-38.
170. Hoyo C, Murphy SK, Schildkraut JM, et al. IGF2R genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites. Dis Markers 2012;32:133-41.
171. Wu Y, Brodt P, Sun H, et al. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 2010;70:57-67.
172. Serino M, Luche E, Gres S, et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012;61:543-53.
173. John BJ, Abulafi AM, Poullis A, et al. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people. Gut 2007;56:1034-5.
174. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-16.
175. Cani PD, Osto M, Geurts L, et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279-88.
176. Rocha C Santos, Lakhdari O, Blottiere HM, et al. Anti-inflammatory properties of dairy lactobacilli. Inflamm Bowel Dis 2012;18:657-66.
177. DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008;83:460-9.
178. Pearson JR, Gill CI, Rowland IR. Diet, fecal water, and colon cancer- development of a biomarker. Nutr Rev 2009;67:509-26.
179. Islam KB, Fukiya S, Hagio M, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011;141:1773-81.
180. Zhu Y, Luo T Michelle, Jobin C, et al. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011;309:119-27.
181. McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. JNatl Cancer Inst 1985;75:185-91.
182. Everson GT, McKinley C, Kern F Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991;87:237-46.
183. Danese E, Montagnana M, Minicozzi AM, et al. The role of resistin in colorectal cancer. Clin Chim Acta 2012;413:760-4.
184. Lee YJ, Myung SK, Cho B, et al. Adiposity and the risk of colorectal adenomatous polyps: a meta-analysis. Cancer Causes Control 2011;22:1021-35.